Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30308312 | 1.00 | CYP2A6 (0.51) | CYP2A6MAPK11MAPK14CHRNA7MCL1 | |
| SCHEMBL28936102 | 0.92 | MAPK11 (0.48) | CYP2A6MAPK11MAPK14CHRNA7MCL1 | |
| SCHEMBL103922 | 0.85 | TUBB4A (0.56) | CYP2A6CHRNA7KDM4EHCAR3TUBB4A | |
| SCHEMBL30233739 | 0.85 | TUBB4A (0.56) | CYP2A6CHRNA7KDM4EHCAR3TUBB4A | |
| SCHEMBL2610256 | 0.85 | CYP2A6 (0.51) | CYP2A6MAPK11MAPK14CHRNA7KDM2B | |
| SCHEMBL4102767 | 0.84 | AR (0.53) | CYP2A6MAPK11MAPK14CHRNA7KDM2B | |
| Hydrazine SCHEMBL1997343 | 0.82 | TUBB4A (0.54) | CYP2A6CHRNA7KDM4EHCAR3TUBB4A | |
| SCHEMBL30317473 | 0.81 | MAPK11 (0.53) | CYP2A6MAPK11MAPK14CHRNA7KDM2B | |
| SCHEMBL30623233 | 0.81 | KDM4E (0.56) | CYP2A6MAPK11MAPK14CHRNA7KDM2B | |
| SCHEMBL232145 | 0.81 | KDM4E (0.56) | CYP2A6MAPK11MAPK14CHRNA7KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| EP-2155739-B1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | claimed |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | claimed |
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | claimed |
| WO-2010086366-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-08-05 | — | — | WO | claimed |
| CN-122039051-A | Composite coating for high-wear-resistance sliding bearing and preparation method thereof | 成都工业职业技术学院 | 2026-05-15 | — | — | CN | disclosed |
| WO-2025231152-A1 | COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| CN-116239768-B | Indole polyketone and preparation method thereof | 南阳师范学院 | 2024-11-08 | — | — | CN | disclosed |
| CN-116253673-B | Indole sulfonated monomer, indole sulfonated polymer, proton exchange membrane and preparation method thereof | 南阳师范学院 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024179405-A1 | CLASS OF CINNAMAMIDE DERIVATIVES AND APPLICATION THEREOF | 上海交通大学 | 2024-09-06 | — | — | WO | disclosed |
| CN-118546081-A | Cinnamide derivative and application thereof | 上海交通大学 | 2024-08-27 | — | — | CN | disclosed |
| EP-0915872-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-19 | — | — | EP | disclosed |
| WO-1999020623-A1 | INDOLE DERIVATIVE USEFUL AS ENDOTHELIN RECEPTOR ANTAGONIST | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| US-5856517-A | ANTIPROLIFERATIVE AGENTS USEFUL IN THE TREATMENT OF CANCER. | HOFFMANN-LA ROCHE INC. (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0539117-B1 | Compounds useful as leukotriene antagonists | LILLY CO ELI (GB) | 1998-03-11 | — | — | EP | disclosed |
| WO-1998004552-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 1998-02-05 | — | — | WO | disclosed |
| US-5410061-A | Leukotriene antagonist | LILLY INDUSTRIES LIMITED (GB) | 1995-04-25 | — | — | US | disclosed |
| EP-0539117-A1 | Compounds useful as leukotriene antagonists | LILLY INDUSTRIES LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
| EP-0409027-A1 | Indole derivatives, process for their preparation and their use in pharmaceuticals | BAYER AG (DE) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | CYP2A6 127/4885MAPK11 480/4885MAPK14 796/4885 |
| US-20100222328-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | HCRTR2, HCRTR1, NPY2R | CYP2A6 692/4885MAPK11 3680/4885MAPK14 4093/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | CYP2A6 3494/4885MAPK11 839/4885MAPK14 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.